Prenetics Global Limited(PRE)Earnings, Financials & Key Ratios

PRE•NASDAQ

$17.49

Price updated Jul 6, 2026

SectorHealthcare IndustryDiagnostics & Research Sub-IndustryPoint-of-Care and Rapid Testing

AboutPrenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.Show more

Revenue$92M+201.7%
EBITDA-$34M+18.6%
Net Income-$38M+18.6%
EPS (Diluted)-2.68+26.4%
Gross Margin52.81%+5.0%
EBITDA Margin-37.18%+73.0%
Operating Margin-41.27%+73.8%
Net Margin-40.81%+73.0%
ROE-21.81%+10.2%

PRE Price & Volume

Prenetics Global Limited (PRE) stock price & volume — 10-year historical chart

Loading chart...

Rapid Revenue Scaling Faces Severe Profitability Headwinds

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Accelerating

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Rapid cash reserve depletion

Key Thesis Takeaways

Prenetics is currently navigating a high-stakes transition from legacy pandemic testing to specialized clinical diagnostics, evidenced by a 107.7% year-over-year revenue growth in 2026Q1.
While the company has successfully improved gross margins to 64.8%, the business model remains fundamentally challenged by persistent operating losses and a -27.0% operating margin.
Investors should exercise caution as the firm continues to burn cash, evidenced by a -33.7% free cash flow margin, while simultaneously engaging in capital-intensive share repurchases.

Verdict Logic

the company's inability to generate positive operating cash flow, evidenced by a 0.52 OCF/NI ratio, suggests that current capital allocation strategies are unsustainable without further dilutive financing.

PRE Growth Metrics

Prenetics Global Limited (PRE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years7.23%

3 Years91.46%

TTM173.96%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-47.61%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-20.21%

Return on Capital

10 Years-45.83%

5 Years-39.96%

3 Years-22.77%

Last Year-21.61%

PRE Recent Earnings

Prenetics Global Limited (PRE) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 5/12 qtrs (45%)●Beat Revenue 4/12 qtrs (36%)

Q3 2026Latest

Jun 10, 2026

Metric

Actual

Est

EPS

$0.56-14.3%

$0.49

Rev

$36M-0.1%

$36M

Q2 2026

May 14, 2026

Metric

Actual

Est

EPS

$1.14-131.6%

$0.49

Rev

$36M-2.3%

$37M

Q1 2026

Feb 18, 2026

Metric

Actual

Est

EPS

$0.27+44.9%

$0.49

Rev

$37M+9.5%

$33M

Q4 2025

Nov 10, 2025

Metric

Actual

Est

EPS

$0.41+25.5%

$0.55

Rev

$24M-38.5%

$38M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q3 2026Latest	Jun 10, 2026	$0.56vs $0.49-14.3%	$36Mvs $36M-0.1%
Q2 2026	May 14, 2026	$1.14vs $0.49-131.6%	$36Mvs $37M-2.3%
Q1 2026	Feb 18, 2026	$0.27vs $0.49+44.9%	$37Mvs $33M+9.5%
Q4 2025	Nov 10, 2025	$0.41vs $0.55+25.5%	$24Mvs $38M-38.5%

Based on last 12 quarters of dataView full earnings history →

Latest PRE News

Recent stock market news and headlines for Prenetics Global Limited (PRE)

PRNewsWire·Jun 30, 2026

CELEBRITY RIVER CRUISES INNOVATES PRE- AND POST-CRUISE EXPERIENCES WITH LAUNCH OF BEFORE AND AFTER STAYS IN FOUR EUROPEAN CITIES

Unlock more of Europe with immersive destination discovery and personalized experiences, all with Celebrity Cruises' signature hospitality, in Prague, Budapest, Amsterdam and Lausanne. MIAMI, June 30, 2026 /PRNewswire/ -- Starting today, Celebrity River Cruises guests can discover even more of Europe with guided, multi-day Before and After Stays — thoughtfully curated, end-to-end destination experiences.

Peers Comparison

Key metrics vs top competitors for Prenetics Global Limited (PRE)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
PREPrenetics Global LimitedCurrent	$17.49	$297.34M	-6.53	201.72%	-40.81%	-21.81%	—
EXASExact Sciences Corporation	$104.91	$20.02B	-95.37	17.69%	-6.4%	-8.66%	—
NTRANatera, Inc.	$283.80	$40.64B	-186.71	35.9%	-9.05%	-15.13%	—
CSTLCastle Biosciences, Inc.	$24.21	$734.29M	-29.17	3.66%	-3.77%	-2.77%	—
QDELQuidelOrtho Corporation	$18.00	$1.23B	-1.08	-1.89%	-45.57%	-56.31%	—
AHCOAdaptHealth Corp.	$10.27	$1.4B	-19.75	-0.49%	-2.78%	-5.09%	—

Compare PRE vs Peers

Prenetics Global Limited (PRE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs EXAS

Most directly comparable listed peer for PRE.

Scale Benchmark

vs TMO

Larger-name benchmark to compare PRE against a more recognizable public peer.

Peer Set

Compare Top 5

vs EXAS, NTRA, CSTL, QDEL

Get notified when PRE posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

PRE Frequently Asked Questions

Prenetics Global Limited (PRE) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Prenetics Global Limited's revenue?

Prenetics Global Limited (PRE) reported $113.7M in revenue for fiscal year 2025. This represents a 1132% increase from $9.2M in 2019.

How fast is Prenetics Global Limited growing?

Prenetics Global Limited (PRE) grew revenue by 201.7% over the past year. This is strong growth.

Is PRE profitable?

Prenetics Global Limited (PRE) reported a net loss of $71.0M for fiscal year 2025.

Dividend & Returns

What is PRE's return on equity?

Prenetics Global Limited (PRE) has a return on equity (ROE) of -21.8%. Negative ROE indicates the company is unprofitable.

What is Prenetics Global Limited's free cash flow?

Prenetics Global Limited (PRE) had negative free cash flow of $34.1M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in PRE back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q3 2026Latest

Jun 10, 2026

$0.56vs $0.49-14.3%

$36Mvs $36M-0.1%

Q2 2026

May 14, 2026

$1.14vs $0.49-131.6%

$36Mvs $37M-2.3%

Q1 2026

Feb 18, 2026

$0.27vs $0.49+44.9%

$37Mvs $33M+9.5%

Q4 2025

Nov 10, 2025

$0.41vs $0.55+25.5%

$24Mvs $38M-38.5%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

PREPrenetics Global LimitedCurrent

$17.49

$297.34M

-6.53

201.72%

-40.81%

-21.81%

—

EXASExact Sciences Corporation

$104.91

$20.02B

-95.37

17.69%

-6.4%

-8.66%

—

NTRANatera, Inc.

$283.80

$40.64B

-186.71

35.9%

-9.05%

-15.13%

—

CSTLCastle Biosciences, Inc.

$24.21

$734.29M

-29.17

3.66%

-3.77%

-2.77%

—

QDELQuidelOrtho Corporation

$18.00

$1.23B

-1.08

-1.89%

-45.57%

-56.31%

—

AHCOAdaptHealth Corp.

$10.27

$1.4B

-19.75

-0.49%

-2.78%

-5.09%

—